Victory Capital Management
IRD

Victory Capital Management’s Opus Genetics IRD Stock Holding History

Victory Capital Management’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-46,916
Closed -$141K – 2592
2023
Q4 		$141K Buy
+46,916
New +$139K ﹤0.01% 2288
2020
Q2 		– Sell
-334
Closed -$2K – 3337
2020
Q1 		$2K Buy
+334
New +$2.9K ﹤0.01% 3689
2019
Q4 		– Sell
-171
Closed -$1K – 3326
2019
Q3 		$1K Buy
+171
New +$2.38K ﹤0.01% 3731

Other funds holding IRD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RB
Richmond Brothers Jackson, Michigan $150M AUM 14.02% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Victory Capital Management's IRD Position: Q1 2024 in Review

Victory Capital Management sold out of Opus Genetics (IRD) in Q1 2024, closing a stake of 46,916 shares — an estimated $141K sold.

Victory Capital Management first reported a position in IRD in Q3 2019 and held it in 3 quarters. The position peaked at $141K in Q4 2023. 49 funds tracked by Wall St. Rank hold IRD as of Q1 2024.

  • Victory Capital Management reported no remaining Opus Genetics position as of Q1 2024 after selling out during the quarter.
  • Victory Capital Management sold 46,916 Opus Genetics shares in Q1 2024, an estimated $141K.
  • Victory Capital Management first reported a position in Opus Genetics in Q3 2019 and held it in 3 quarters.
  • Victory Capital Management's Opus Genetics position peaked at $141K in Q4 2023.
  • 49 funds tracked by Wall St. Rank held Opus Genetics as of Q1 2024.

Based on Victory Capital Management's 13F filing for Q1 2024, filed 3 May 2024.